HYDERABAD, India — Aurobindo Pharma said on Friday it plans to open a second U.S. plant for injectable products.
According to the Hindustan Times, the announcement comes on the heels of President Trump calling on pharmaceutical companies to make more drugs locally. Aurobindo, India’s fourth-biggest drug maker by sales, earns more than half of its revenue in the United States.
“With the current landscape of what’s happening with the U.S. White House administration, and some of the things that may change there, clearly, we don’t think having capacity in the U.S. would be detrimental at this point,” Aurobindo’s U.S. chief, Bob Cunard, told an earnings briefing.
The injectable drugs factory is expected to be at Aurobindo’s New Jersey site.
Trump has proposed a “border tax” on U.S. imports, something that has “worried some” in India’s roughly $15 billion pharmaceutical industry that supplies approximately 30% of the medicines sold in the U.S.